Jubilant Pharmova Ltd
Jubilant Pharmova Ltd Q4 FY25 Results & Presentation Highlights: Revenue, Margins & Order Book
Q4 FY25 investor presentation: what the company reported on revenue, margins and projects.
Based on Jubilant Pharmova Ltd's Q4 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Q4 FY25 EBITDA: Rs.
From Jubilant Pharmova Ltd's Q4 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q4 FY25 consolidated revenue grew 10% YoY to Rs. 1,929 Cr.
- Full year FY25 revenue grew 8% YoY to Rs. 7,235 Cr.
- Specific segments:
- Revenue grew 31% YoY to Rs. 340 Cr. (Page 46)
- Revenue increased 33% YoY to Rs. 156 Cr. (Page 53)
- Revenue increased 11% YoY to Rs. 182 Cr. (Page 58)
- Revenue increased 2% YoY to Rs. 192 Cr. (Page 39)
- Some segments showed decline due to product focus, e.g., 22% decrease YoY to Rs. 157 Cr. (Page 64)
- Outlook for FY26: Continue revenue growth momentum and expand EBITDA margins (Page 94)
2 more points management made on revenue & sales performance
Profitability & Margins
See what Jubilant Pharmova Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Spokane, Washington, USA expansion: Lines 3 & 4, total investment USD 285 million (RoCE > 20%) including USD 150 million US Govt. funding. Line 3 media-fill and product qualification completed; commercial production expected to start FY26. Revenue potential USD 160-180 million. Full capacity utilization expected in 3 years (vs 4 years earlier).
- Current sites Greater Noida & Bengaluru: Expansion ongoing with capacity 1,000 FTEs FY25, 2,000 FTEs FY26, 4,000 FTEs FY27. Total capex USD 150 million, expected RoCE > 20%.
- PET radiopharmaceuticals expansion: Fully operational by FY28 with funding from internal accruals and long-term credit; USD 50 million investment targeting asset turnover 1.0x and RoCE > 20%.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Jubilant Pharmova Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Jubilant Pharmova Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹2.3K Cr, net profit ₹119 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Jubilant Pharmova Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q4 FY24 earnings call analysis →
- Q1 FY25 earnings call analysis →
- Q2 FY25 earnings call analysis →
- Q3 FY25 earnings call →
- Q3 FY23 earnings call →
- Q2 FY23 earnings call →
- Q1 FY23 earnings call →
- Q4 FY22 earnings call →
- Q3 FY22 earnings call →
- Q1 FY22 earnings call →
- Q4 FY21 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Anuh Pharma Ltd (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare Ltd (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key investor presentation takeaways from Themis Medicare Ltd's Q4 FY25 investor presentation — and how it ranks against sector p
- Lincoln Pharmaceuticals Ltd (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key investor presentation takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 investor presenta
- Kopran Ltd (Q4 FY25)
1,372 Lakhs (~7.37% decline) . Key investor presentation takeaways from Kopran Ltd's Q4 FY25 investor presentation — and how it ranks against sector peers.
Frequently Asked Questions
What were Jubilant Pharmova Ltd Q4 FY25 results?
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Q4 FY25 EBITDA: Rs.
What is Jubilant Pharmova Ltd share price analysis?
Jubilant Pharmova Ltd currently shows a neutral. The stock trades at a P/E of 43.7 with a market cap of ₹16,972 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jubilant Pharmova Ltd planning capital expenditure?
Spokane, Washington, USA expansion: Lines 3 & 4, total investment USD 285 million (RoCE > 20%) including USD 150 million US Govt.
Keep Jubilant Pharmova Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.